Iovance Biotherapeutics, Inc. IOVA Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease ROU assets of $44.38M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease ROU assets changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease ROU assets decreased by 12.8% year-over-year, from $50.9M to $44.38M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease ROU assets has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.